PL3097086T3 - (2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i - Google Patents

(2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i

Info

Publication number
PL3097086T3
PL3097086T3 PL15701577T PL15701577T PL3097086T3 PL 3097086 T3 PL3097086 T3 PL 3097086T3 PL 15701577 T PL15701577 T PL 15701577T PL 15701577 T PL15701577 T PL 15701577T PL 3097086 T3 PL3097086 T3 PL 3097086T3
Authority
PL
Poland
Prior art keywords
oxazepane
carboxamides
phenylethyl
cyano
inhibitors
Prior art date
Application number
PL15701577T
Other languages
English (en)
Polish (pl)
Inventor
Hans Roland Lönn
Stephen Connolly
Steven Swallow
Staffan PO KARLSSON
Carl-Johan Aurell
John Fritiof PONTÉN
Kevin James Doyle
Amanda Jane Van De Poël
Graham Peter Jones
David Wyn Watson
Jaqueline Anne Macritchie
Nicholas John Palmer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52432834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3097086(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3097086T3 publication Critical patent/PL3097086T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL15701577T 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i PL3097086T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931090P 2014-01-24 2014-01-24
PCT/GB2015/050155 WO2015110826A1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors
EP15701577.7A EP3097086B1 (en) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors

Publications (1)

Publication Number Publication Date
PL3097086T3 true PL3097086T3 (pl) 2018-04-30

Family

ID=52432834

Family Applications (3)

Application Number Title Priority Date Filing Date
PL15701577T PL3097086T3 (pl) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i
PL17195612T PL3323814T3 (pl) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i
PL20173862.2T PL3744714T3 (pl) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL17195612T PL3323814T3 (pl) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i
PL20173862.2T PL3744714T3 (pl) 2014-01-24 2015-01-23 (2s)-n-[(1s)-1-cyjano-2-fenyloetylo]-1,4-oksazepano-2-karboksyamidy jako inhibitory peptydazy dipeptydylowej i

Country Status (39)

Country Link
US (18) US9522894B2 (enExample)
EP (4) EP3097086B1 (enExample)
JP (7) JP6469711B2 (enExample)
KR (1) KR102417684B1 (enExample)
CN (2) CN110483492B (enExample)
AP (1) AP2016009322A0 (enExample)
AR (1) AR099177A1 (enExample)
AU (4) AU2015208932C1 (enExample)
BR (1) BR112016016224B1 (enExample)
CA (1) CA2935625C (enExample)
CL (1) CL2016001889A1 (enExample)
CR (1) CR20160327A (enExample)
CY (2) CY1120049T1 (enExample)
DK (3) DK3323814T3 (enExample)
DO (1) DOP2016000175A (enExample)
EA (1) EA032794B1 (enExample)
ES (3) ES2808060T3 (enExample)
FI (1) FI3744714T3 (enExample)
HK (1) HK1225730B (enExample)
HR (3) HRP20180116T1 (enExample)
HU (3) HUE070606T2 (enExample)
IL (3) IL246614B (enExample)
LT (3) LT3097086T (enExample)
MX (1) MX368840B (enExample)
MY (1) MY194850A (enExample)
NO (1) NO2699580T3 (enExample)
NZ (2) NZ722063A (enExample)
PE (1) PE20161218A1 (enExample)
PH (1) PH12016501439B1 (enExample)
PL (3) PL3097086T3 (enExample)
PT (3) PT3323814T (enExample)
RS (3) RS60639B1 (enExample)
SG (2) SG10201701056QA (enExample)
SI (3) SI3744714T1 (enExample)
SM (3) SMT202000433T1 (enExample)
TW (1) TWI690517B (enExample)
UY (1) UY35963A (enExample)
WO (1) WO2015110826A1 (enExample)
ZA (2) ZA201605856B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
KR20230054480A (ko) * 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
US20200390781A1 (en) * 2018-02-07 2020-12-17 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
KR102738945B1 (ko) 2018-03-01 2024-12-04 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
US20210252015A1 (en) * 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
CN111689923B (zh) * 2019-03-12 2022-11-08 中国科学院上海药物研究所 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途
PH12022550895A1 (en) * 2019-10-23 2023-03-27 Chong Kun Dang Pharmaceutical Corp Compositions for preventing or treating chronic obstructive pulmonary diseases (copd)
CA3181285A1 (en) * 2020-07-20 2022-01-27 Jessica BASSO Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
RS66302B1 (sr) * 2020-08-26 2025-01-31 Haisco Pharmaceuticals Pte Ltd Derivat nitrila koji deluje kao inhibitor dipeptidil peptidaze 1 i njegova upotreba
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN114159446A (zh) * 2020-09-11 2022-03-11 中国科学院上海营养与健康研究所 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
EP4257588A4 (en) * 2020-12-04 2024-10-16 Reistone Biopharma Company Limited SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND ITS MEDICINAL USE
WO2022140516A1 (en) * 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN116783189A (zh) * 2021-02-05 2023-09-19 南京明德新药研发有限公司 含1，4-氧杂氮杂环庚烷的并环类衍生物
JP2024516826A (ja) * 2021-04-29 2024-04-17 インスメッド インコーポレイテッド 嚢胞性線維症を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
KR20240099179A (ko) * 2021-10-29 2024-06-28 인스메드 인코포레이티드 만성 비부비동염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
CN116332937A (zh) * 2021-12-23 2023-06-27 杭州邦顺制药有限公司 二肽基肽酶ⅰ抑制剂及其用途
US20250101011A1 (en) * 2022-01-11 2025-03-27 Shanghai Yidian Pharmaceutical Technology Development Co., Ltd Peptidyl nitrile compound and use thereof
GB2630719A (en) * 2022-02-16 2024-12-04 Insmed Inc Certain N-(1-cynao-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa
KR20240150486A (ko) * 2022-02-22 2024-10-15 하이스코 파마수티컬즈 피티이. 엘티디. 질소-함유 헤테로사이클릭 화합물의 제조 방법
US20250163036A1 (en) * 2022-02-22 2025-05-22 Haisco Pharmaceuticals Pte. Ltd. Dipeptidyl peptidase 1 inhibitor polymorph, preparation method and use therefor
KR20240153351A (ko) * 2022-02-22 2024-10-22 하이스코 파마수티컬즈 피티이. 엘티디. 디펩티딜 펩티다제 억제제 화합물의 염 및 결정형
CN114644562B (zh) * 2022-04-29 2023-08-22 常州大学 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用
JP2025518345A (ja) * 2022-06-07 2025-06-12 瑞石生物医薬有限公司 ベンゾ［ｃ］クロマン化合物の薬学的に許容される塩、ならびに薬学的に許容される塩の多形及び使用
US20250353839A1 (en) * 2022-06-07 2025-11-20 Reistone Biopharma Company Limited Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
CN119317620A (zh) 2022-06-13 2025-01-14 亚力维克希斯股份有限公司 氮杂环烷基羰基环状胺化合物
EP4551554A1 (en) 2022-07-06 2025-05-14 Chiesi Farmaceutici S.p.A. Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors
EP4602043A1 (en) 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
WO2024088307A1 (zh) * 2022-10-26 2024-05-02 上海壹迪生物技术有限公司 一种新型肽基腈类化合物及其应用
CN115785083A (zh) * 2022-12-27 2023-03-14 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂及其制备方法
CN120584108A (zh) 2023-01-06 2025-09-02 英斯梅德股份有限公司 新型可逆dpp1抑制剂及其用途
WO2024173556A2 (en) * 2023-02-15 2024-08-22 Insmed Incorporated Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors
WO2024193695A1 (zh) * 2023-03-23 2024-09-26 西藏海思科制药有限公司 一种二肽基肽酶小分子抑制剂的药物组合物
WO2025059526A1 (en) * 2023-09-15 2025-03-20 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof
USD1099133S1 (en) * 2024-02-01 2025-10-21 Apple Inc. Display screen or portion thereof showing a graphical user interface
WO2025214073A1 (en) * 2024-04-12 2025-10-16 Insmed Incorporated Dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2782151B2 (ja) 1993-07-16 1998-07-30 博 吉田 衝撃吸収柵用の端ストッパ
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
WO2002020804A1 (en) 2000-09-08 2002-03-14 Prozymex A/S Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses
ATE407924T1 (de) 2000-10-06 2008-09-15 Mitsubishi Tanabe Pharma Corp Stickstoffhaltige, fünfgliedrige ringverbindungen
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
AU2002352126A1 (en) 2001-12-04 2003-06-17 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
ATE399763T1 (de) 2003-05-30 2008-07-15 Prozymex As Proteasehemmer
US20070099958A1 (en) * 2003-06-18 2007-05-03 Prozymex A/S Protease inhibitors
SG152226A1 (en) 2004-04-07 2009-05-29 Rinat Neuroscience Corp Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US20070286854A1 (en) 2004-04-28 2007-12-13 Bayer Healthcare Ag Diagnostics And Therapeutics For Diseases Associated With Dipeptidyl-Peptidase 1 (Dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
NZ552208A (en) 2004-06-29 2008-11-28 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
CN103251953A (zh) 2004-07-19 2013-08-21 约翰·霍普金斯大学 供免疫抑制的flt3抑制剂
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
WO2007005668A2 (en) 2005-06-30 2007-01-11 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2008109181A2 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2009026701A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Sirtuin inhibitors
US20100282247A1 (en) 2007-09-25 2010-11-11 Novartis Ag Treatment of pulmonary disorders with aerosolized medicaments such as vancomycin
EA201000958A1 (ru) * 2007-12-12 2010-12-30 Астразенека Аб Пептидилнитрилы и их применение в качестве ингибиторов дипептидилпептидазы i
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
CN102438595B (zh) 2009-04-01 2016-04-27 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
EP2427445A1 (en) * 2009-05-07 2012-03-14 AstraZeneca AB Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
IT1404036B1 (it) 2010-12-17 2013-11-08 Oto Melara Spa Veicolo armato con struttura migliorata.
KR20140048857A (ko) 2011-02-11 2014-04-24 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 카텝신 c 억제제
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
EP2817310B1 (en) 2012-02-21 2018-03-21 Merck Patent GmbH 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
CN104284895B (zh) 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
WO2014140081A1 (en) 2013-03-14 2014-09-18 Boehringer Ingelheim International Gmbh Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
AU2014230814B2 (en) 2013-03-14 2017-12-21 Boehringer Ingelheim International Gmbh Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
JP6441831B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
WO2015027039A1 (en) 2013-08-22 2015-02-26 Emory University Devices and methods related to airway inflammation
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
EA029030B1 (ru) 2013-09-09 2018-01-31 Прозюмекс А/С Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (enExample) 2014-01-24 2018-02-24
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
MX2016013245A (es) 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
PL3466432T3 (pl) 2014-05-15 2021-02-08 Insmed Incorporated Sposoby leczenia zakażeń płuc niegruźliczymi mykobakteriami
EP3149192B1 (en) 2014-05-30 2019-01-02 Versitech Limited Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
PL3191487T3 (pl) 2014-09-12 2020-03-31 Boehringer Ingelheim International Gmbh Spirocykliczne inhibitory katepsyny C
BR112017009595A2 (pt) 2014-11-14 2017-12-19 Boehringer Ingelheim Int morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
AU2016227618B2 (en) 2015-03-05 2020-06-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
KR20230054480A (ko) 2016-07-29 2023-04-24 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
US20200390781A1 (en) 2018-02-07 2020-12-17 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
KR102738945B1 (ko) 2018-03-01 2024-12-04 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
US20210252015A1 (en) 2018-07-17 2021-08-19 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
EP3955889A1 (en) 2019-04-17 2022-02-23 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
JP2024516826A (ja) 2021-04-29 2024-04-17 インスメッド インコーポレイテッド 嚢胞性線維症を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
KR20240099179A (ko) 2021-10-29 2024-06-28 인스메드 인코포레이티드 만성 비부비동염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
GB2630719A (en) 2022-02-16 2024-12-04 Insmed Inc Certain N-(1-cynao-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Also Published As

Publication number Publication date
US20200247765A1 (en) 2020-08-06
AU2019202675A1 (en) 2019-05-16
JP6804570B2 (ja) 2020-12-23
US20230085620A1 (en) 2023-03-23
AR099177A1 (es) 2016-07-06
US20230033573A1 (en) 2023-02-02
US20230115170A1 (en) 2023-04-13
JP7157791B2 (ja) 2022-10-20
EP4548972A3 (en) 2025-06-25
AU2015208932B8 (en) 2017-03-09
PT3744714T (pt) 2025-04-07
JP2021046423A (ja) 2021-03-25
HUE038274T2 (hu) 2018-10-29
US20210238152A1 (en) 2021-08-05
NO2699580T3 (enExample) 2018-02-24
PH12016501439A1 (en) 2017-02-06
PT3097086T (pt) 2018-02-21
US11773069B2 (en) 2023-10-03
US20230025351A1 (en) 2023-01-26
CL2016001889A1 (es) 2016-12-09
SI3323814T1 (sl) 2020-10-30
US11655224B2 (en) 2023-05-23
CN105980367A (zh) 2016-09-28
EA032794B1 (ru) 2019-07-31
US10287258B2 (en) 2019-05-14
EP3323814B1 (en) 2020-05-13
EA201691375A1 (ru) 2017-01-30
RS66709B1 (sr) 2025-05-30
US20230028726A1 (en) 2023-01-26
EP3744714B1 (en) 2025-01-15
JP7628587B2 (ja) 2025-02-10
PE20161218A1 (es) 2016-11-27
SI3744714T1 (sl) 2025-05-30
KR20160111470A (ko) 2016-09-26
US11117874B2 (en) 2021-09-14
US12054465B2 (en) 2024-08-06
AU2017200338B2 (en) 2018-03-01
AP2016009322A0 (en) 2016-07-31
CN110483492B (zh) 2023-07-21
CY1123391T1 (el) 2021-12-31
IL265611A (en) 2019-05-30
ES2658516T3 (es) 2018-03-12
SG10201701056QA (en) 2017-03-30
AU2015208932A8 (en) 2017-03-09
US11680049B2 (en) 2023-06-20
PT3323814T (pt) 2020-08-05
EP4548972A2 (en) 2025-05-07
CN105980367B (zh) 2019-08-23
LT3097086T (lt) 2018-02-26
AU2015208932C1 (en) 2017-05-25
US20240336582A1 (en) 2024-10-10
CA2935625C (en) 2022-10-18
JP6469711B2 (ja) 2019-02-13
KR102417684B1 (ko) 2022-07-05
US20150210655A1 (en) 2015-07-30
ES2808060T3 (es) 2021-02-25
EP3744714A1 (en) 2020-12-02
AU2018202956B2 (en) 2019-05-09
FI3744714T3 (fi) 2025-04-01
RS60639B1 (sr) 2020-09-30
US20230069044A1 (en) 2023-03-02
EP3097086B1 (en) 2017-12-13
MY194850A (en) 2022-12-19
IL252836A0 (en) 2017-08-31
RS56919B1 (sr) 2018-05-31
AU2019202675B2 (en) 2020-05-28
AU2017200338A1 (en) 2017-02-02
PL3744714T3 (pl) 2025-09-08
PH12016501439B1 (en) 2017-02-06
ZA201800431B (en) 2019-09-25
AU2015208932B2 (en) 2017-02-16
SMT202500137T1 (it) 2025-05-12
MX2016009349A (es) 2016-10-13
US20180251436A1 (en) 2018-09-06
JP2025072423A (ja) 2025-05-09
NZ734768A (en) 2022-09-30
JP2025157389A (ja) 2025-10-15
TWI690517B (zh) 2020-04-11
US20240132455A1 (en) 2024-04-25
IL246614B (en) 2018-02-28
US11814359B2 (en) 2023-11-14
EP3323814A1 (en) 2018-05-23
MX368840B (es) 2019-10-18
DK3323814T3 (da) 2020-08-03
US11655222B2 (en) 2023-05-23
EP3097086A1 (en) 2016-11-30
DK3744714T3 (da) 2025-04-07
JP2022096662A (ja) 2022-06-29
HRP20250302T1 (hr) 2025-04-25
ES3018635T3 (es) 2025-05-16
HUE052421T2 (hu) 2021-04-28
US20230116721A1 (en) 2023-04-13
US9815805B2 (en) 2017-11-14
CY1120049T1 (el) 2018-12-12
JP7336563B2 (ja) 2023-08-31
DK3097086T3 (en) 2018-02-05
CR20160327A (es) 2016-10-20
BR112016016224B1 (pt) 2023-02-23
US20230250071A1 (en) 2023-08-10
US11655223B2 (en) 2023-05-23
US11667615B2 (en) 2023-06-06
ZA201605856B (en) 2020-02-26
HRP20201147T1 (hr) 2020-12-11
US11655221B2 (en) 2023-05-23
JP2017503832A (ja) 2017-02-02
WO2015110826A1 (en) 2015-07-30
JP2019070029A (ja) 2019-05-09
PL3323814T3 (pl) 2020-10-19
LT3323814T (lt) 2020-10-26
SI3097086T1 (en) 2018-04-30
TW201612167A (en) 2016-04-01
SMT201800058T1 (it) 2018-03-08
JP2023156479A (ja) 2023-10-24
US9522894B2 (en) 2016-12-20
NZ722063A (en) 2017-09-29
JP7714823B2 (ja) 2025-07-29
AU2015208932A1 (en) 2016-07-28
SG11201606052TA (en) 2016-08-30
HRP20180116T1 (hr) 2018-03-23
HUE070606T2 (hu) 2025-06-28
US11673872B2 (en) 2023-06-13
HK1255870A1 (en) 2019-08-30
US20230062646A1 (en) 2023-03-02
BR112016016224A2 (enExample) 2017-08-08
UY35963A (es) 2015-07-31
DOP2016000175A (es) 2016-08-15
CN110483492A (zh) 2019-11-22
US11673871B2 (en) 2023-06-13
LT3744714T (lt) 2025-04-10
US20230278969A1 (en) 2023-09-07
HK1225730B (en) 2017-09-15
CA2935625A1 (en) 2015-07-30
AU2018202956A1 (en) 2018-05-17
US10669245B2 (en) 2020-06-02
US20200017455A1 (en) 2020-01-16
SMT202000433T1 (it) 2020-09-10
US20170057938A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
IL265611A (en) (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
DK3265452T3 (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
IL256347A (en) New thrombin inhibitors